Tumoral parkinsonism—Parkinsonism secondary to brain tumors, paraneoplastic syndromes, intracranial malformations, or oncological intervention, and the effect of dopaminergic treatment
(2023) In Brain and Behavior 13(8).- Abstract
Introduction: Secondary tumoral parkinsonism is a rare phenomenon that develops as a direct or indirect result of brain neoplasms or related conditions. Objectives: The first objective was to explore to what extent brain neoplasms, cavernomas, cysts, paraneoplastic syndromes (PNSs), and oncological treatment methods cause parkinsonism. The second objective was to investigate the effect of dopaminergic therapy on the symptomatology in patients with tumoral parkinsonism. Methods: A systematic literature review was conducted in the databases PubMed and Embase. Search terms like “secondary parkinsonism,” “astrocytoma,” and “cranial irradiation” were used. Articles fulfilling inclusion criteria were included in the review. Results: Out of... (More)
Introduction: Secondary tumoral parkinsonism is a rare phenomenon that develops as a direct or indirect result of brain neoplasms or related conditions. Objectives: The first objective was to explore to what extent brain neoplasms, cavernomas, cysts, paraneoplastic syndromes (PNSs), and oncological treatment methods cause parkinsonism. The second objective was to investigate the effect of dopaminergic therapy on the symptomatology in patients with tumoral parkinsonism. Methods: A systematic literature review was conducted in the databases PubMed and Embase. Search terms like “secondary parkinsonism,” “astrocytoma,” and “cranial irradiation” were used. Articles fulfilling inclusion criteria were included in the review. Results: Out of 316 identified articles from the defined database search strategies, 56 were included in the detailed review. The studies, which were mostly case reports, provided research concerning tumoral parkinsonism and related conditions. It was found that various types of primary brain tumors, such as astrocytoma and meningioma, and more seldom brain metastases, can cause tumoral parkinsonism. Parkinsonism secondary to PNSs, cavernomas, cysts, as well as oncological treatments was reported. Twenty-five of the 56 included studies had tried initiating dopaminergic therapy, and of these 44% reported no, 48% low to moderate, and 8% excellent effect on motor symptomatology. Conclusion: Brain neoplasms, PNSs, certain intracranial malformations, and oncological treatments can cause parkinsonism. Dopaminergic therapy has relatively benign side effects and may relieve motor and nonmotor symptomatology in patients with tumoral parkinsonism. Dopaminergic therapy, particularly levodopa, should therefore be considered in patients with tumoral parkinsonism.
(Less)
- author
- Cedergren Weber, Gustav ; Timpka, Jonathan LU ; Rydelius, Anna LU ; Bengzon, Johan LU and Odin, Per LU
- organization
-
- Neurology, Lund
- Restorative Parkinson Unit (research group)
- MultiPark: Multidisciplinary research focused on Parkinson´s disease
- LU Profile Area: Proactive Ageing
- Diagnostic Radiology, (Lund)
- Neuroradiology (research group)
- Neurosurgery
- StemTherapy: National Initiative on Stem Cells for Regenerative Therapy
- Epilepsy Center
- publishing date
- 2023-08
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- brain neoplasm, levodopa, meningioma, nonmotor symptoms, secondary parkinsonism
- in
- Brain and Behavior
- volume
- 13
- issue
- 8
- article number
- e3151
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- pmid:37433071
- scopus:85164735675
- ISSN
- 2162-3279
- DOI
- 10.1002/brb3.3151
- language
- English
- LU publication?
- yes
- id
- f1fa3fc9-9dbc-496e-adc1-80d44541af87
- date added to LUP
- 2023-09-22 14:41:30
- date last changed
- 2024-04-19 01:19:52
@article{f1fa3fc9-9dbc-496e-adc1-80d44541af87, abstract = {{<p>Introduction: Secondary tumoral parkinsonism is a rare phenomenon that develops as a direct or indirect result of brain neoplasms or related conditions. Objectives: The first objective was to explore to what extent brain neoplasms, cavernomas, cysts, paraneoplastic syndromes (PNSs), and oncological treatment methods cause parkinsonism. The second objective was to investigate the effect of dopaminergic therapy on the symptomatology in patients with tumoral parkinsonism. Methods: A systematic literature review was conducted in the databases PubMed and Embase. Search terms like “secondary parkinsonism,” “astrocytoma,” and “cranial irradiation” were used. Articles fulfilling inclusion criteria were included in the review. Results: Out of 316 identified articles from the defined database search strategies, 56 were included in the detailed review. The studies, which were mostly case reports, provided research concerning tumoral parkinsonism and related conditions. It was found that various types of primary brain tumors, such as astrocytoma and meningioma, and more seldom brain metastases, can cause tumoral parkinsonism. Parkinsonism secondary to PNSs, cavernomas, cysts, as well as oncological treatments was reported. Twenty-five of the 56 included studies had tried initiating dopaminergic therapy, and of these 44% reported no, 48% low to moderate, and 8% excellent effect on motor symptomatology. Conclusion: Brain neoplasms, PNSs, certain intracranial malformations, and oncological treatments can cause parkinsonism. Dopaminergic therapy has relatively benign side effects and may relieve motor and nonmotor symptomatology in patients with tumoral parkinsonism. Dopaminergic therapy, particularly levodopa, should therefore be considered in patients with tumoral parkinsonism.</p>}}, author = {{Cedergren Weber, Gustav and Timpka, Jonathan and Rydelius, Anna and Bengzon, Johan and Odin, Per}}, issn = {{2162-3279}}, keywords = {{brain neoplasm; levodopa; meningioma; nonmotor symptoms; secondary parkinsonism}}, language = {{eng}}, number = {{8}}, publisher = {{John Wiley & Sons Inc.}}, series = {{Brain and Behavior}}, title = {{Tumoral parkinsonism—Parkinsonism secondary to brain tumors, paraneoplastic syndromes, intracranial malformations, or oncological intervention, and the effect of dopaminergic treatment}}, url = {{http://dx.doi.org/10.1002/brb3.3151}}, doi = {{10.1002/brb3.3151}}, volume = {{13}}, year = {{2023}}, }